Baricitinib phosphate,1187595-84-1-Amadis Chemical

Home > Product Catalog > Life science > Inhibitors/Agonists > Baricitinib phosphate

[CAS No.1187595-84-1] A892930 Baricitinib phosphate 98%

Purity	Size	Price	Consult
98%	250mg	$190.00
98%	1g	$533.00

Note*

1.Please click to confirm the discount and stock quantity.

2.Click”Bulk Inquiry”to ask for quotations of other quantity.

3.The price does not include shipping and bank charges.

Bulk Inqulry

Quality Control of [1187595-84-1]

NMR

CNMR

HPLC

LC-MS

Related Doc. of[1187595-84-1]

SDS

Specification

MOL

SDF

Product Details [1187595-84-1]

CAS Number: 1187595-84-1

MDL No.: MFCD25976707

Catalog Number: A892930

EINECS:

Molecular Formula: C₁₆H₂₀N₇O₆PS

Molecular Weight: 469.41

Boiling point:

Melting point:

Flash point:

Density:

Appearance: White powder

Storage: Store in 2-8°C for long term (months)

Chiral Purity:

Optical Rotation:

Refractivity:

Pubchem ID: 44231848

Synonyms: (1-(Ethylsulfonyl)-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)azetidin-3-yl)ethanenitrile phosphate

Smiles: CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3.OP(=O)(O)O

InchiKey: FBPOWTFFUBBKBB-UHFFFAOYSA-N

Inchi: InChI=1S/C16H17N7O2S.H3O4P/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14;1-5(2,3)4/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20);(H3,1,2,3,4)

Safety [1187595-84-1]

GHS Pictogram:

Signal Word: Warning

Class:

Precautionary Statements: P261;P305+P351+P338

UN No.:

Hazard Statements: H302;H315;H319;H335

Packing Group:

Literatures [1187595-84-1]

Sorry, the literature is not available.

Similar of [1187595-84-1]

A892931 1187594-09-7

Baricitinib

Reason:Inhibitors/Agonists

A1010011 1187594-14-4

Ilunocitinib

Reason:Inhibitors/Agonists

Description [1187595-84-1]

Baricitinib, also known as INCB-028050; INCB-28050; LY-3009104, is an oral highly selective JAK1 and JAK2 inhibitor for inflammatory and autoimmune diseases. There are four known JAK enzymes: JAK1, JAK2, JAK3 and TYK2. JAK-dependent cytokines have been implicated in the pathogenesis of a number of inflammatory and autoimmune diseases, suggesting that JAK inhibitors may be useful for the treatment of a broad range of inflammatory conditions. Baricitinib demonstrates approximately 100-fold greater potency of inhibition against JAK1 and JAK2 than JAK3 in kinase assays.

Browsing history